Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Crescita Therpeutc J (TSE:CTX)
TSX:CTX
Holding TSE:CTX?
Track your performance easily
CTX Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$0.36 - C$0.70
Previous CloseC$0.61
Volume300.00
Average Volume (3M)28.42K
Market Cap
C$11.73M
Enterprise ValueC$3.75M
Total Cash (Recent Filing)C$9.01M
Total Debt (Recent Filing)C$1.04M
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Nov 07, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding19,441,171
10 Day Avg. Volume5,400
30 Day Avg. Volume28,420
Standard Deviation0.16
R-Squared0.25
Alpha-0.00641
Financial Highlights & Ratios
Price to Book (P/B)0.67
Price to Sales (P/S)0.68
Price to Cash Flow (P/CF)5.20
P/FCF Ratio5.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Crescita Therpeutc News
PremiumCompany Announcements
Crescita Therapeutics Positions for Growth Amid Q2 Challenges
PremiumCompany Announcements
Crescita Therapeutics Secures Lucrative Manufacturing DealPremiumCompany Announcements
Crescita Secures Exclusive Manufacturing Deal in Healthcare
PremiumCompany Announcements
Crescita Therapeutics to Distribute Revolutionary Injection Device
PremiumCompany Announcements
Crescita Therapeutics Expands with Occy Assets Buy
PremiumCompany Announcements
Crescita Therapeutics Boosts Skincare Portfolio
PremiumCompany Announcements
Crescita Shareholders Back Directors and Incentive PlanPremiumCompany Announcements
Crescita Therapeutics Posts Diverse Q1 2024 EarningsOptions Prices
Currently, No data available
---
Ownership Overview
23.82% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
76.18% Public Companies and
Individual Investors
CTX FAQ
What was Crescita Therpeutc J’s price range in the past 12 months?
Crescita Therpeutc J lowest stock price was C$0.36 and its highest was C$0.70 in the past 12 months.
What is Crescita Therpeutc J’s market cap?
Currently, no data Available
When is Crescita Therpeutc J’s upcoming earnings report date?
Crescita Therpeutc J’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were Crescita Therpeutc J’s earnings last quarter?
Crescita Therpeutc J released its earnings results on Aug 07, 2024. The company reported -C$0.048 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.048.
Is Crescita Therpeutc J overvalued?
According to Wall Street analysts Crescita Therpeutc J’s price is currently Overvalued.
Does Crescita Therpeutc J pay dividends?
Crescita Therpeutc J does not currently pay dividends.
What is Crescita Therpeutc J’s EPS estimate?
Crescita Therpeutc J’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Crescita Therpeutc J have?
Crescita Therpeutc J has 19,381,756 shares outstanding.
What happened to Crescita Therpeutc J’s price movement after its last earnings report?
Crescita Therpeutc J reported an EPS of -C$0.048 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.478%.
Which hedge fund is a major shareholder of Crescita Therpeutc J?
Currently, no hedge funds are holding shares in TSE:CTX
---
Crescita Therpeutc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.70%
12-Months-Change
Fundamentals
Return on Equity
-15.79%
Trailing 12-Months
Asset Growth
-13.48%
Trailing 12-Months
Company Description
Crescita Therpeutc J
Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue.
---
Technical Analysis
---